PE Dual Lists on ASX; Announces Capital Raise to Accelerate

Company Announcement
23 September 2021
PEB DUAL LISTS ON ASX; ANNOUNCES CAPITAL RAISE TO ACCELERATE EXECUTION OF
GROWTH OPPORTUNITIES

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to announce that it has been admitted to
the official list of the Australian Securities Exchange (ASX) as a foreign exempt listing and is conducting an equity
raise consisting of a placement of NZ$60 million* (A$58.1 million
1
) with a Retail Offer of up to NZ$20 million
(A$19.4 million) to eligible investors** to capitalise on recent commercial milestones and to accelerate the
execution of its growth strategy in markets of scale.

Pacific Edge Admitted as Foreign Exempt Listing on ASX

The ASX has approved Pacific Edge’s application for a foreign exempt listing on the ASX and admitted the
Company to the official list of ASX on the evening of 22 September 2021. Trading of Pacific Edge’s shares on ASX is
expected to commence at 11:00am (AEST) / 2:00pm (NZDT) on Monday 27 September 2021, enabling
shareholders to trade their Pacific Edge shares on the NZX or ASX.

Pacific Edge has been allocated the ASX ticker code of "PEB". To trade on either exchange, shares will need to be
registered on the share register for the particular jurisdiction. Shareholders wishing to move their shares to the
ASX or NZX register should contact either their share broker or Pacific Edge's share registry, Link Market Services
Limited, either by calling 09 375 5998 or email enquiries@linkmarketservices.co.nz. Pacific Edge will proudly
remain a New Zealand company and continue its primary listing on the NZX.

Capital Raising to Accelerate Growth Opportunities

Pacific Edge is conducting an equity raise to capitalise on recent commercial milestones and execute and
accelerate its growth strategy in markets of scale.

Funds raised will be used as follows:
 The majority of the funds will be used to accelerate growth in the company’s key US market;
 To further develop and grow the commercial process in Southeast Asia targeting both primary care and
secondary care physicians;
 To further leverage the company’s first mover advantage in the detection and management of urothelial
cancer;
 To potentially develop and grow new product opportunities by leveraging the company’s intellectual
property across other cancers that can be detected in urine; and
 To maintain a prudent cash buffer for balance sheet management and working capital purposes as the
company transitions to profitability.


1
Based on a NZD/AUD exchange rate of 0.9683 as at 22 September 2021.
* With the ability for Pacific Edge to increase the size of the placement at its discretion.
** With the ability to accept oversubscriptions, subject to demand and at the discretion of the Board.

Company Announcement
23 September 2021
Pacific Edge has a well defined growth strategy and its primary focus remains to grow the adoption of multiple
Cxbladder products by an increasing number of large scale institutional accounts in each of the company’s
targeted markets. Positive progress is being made on strategic initiatives and, despite the ongoing impact from
Covid-19 and the recent escalation of the Delta variant, the company continues to deliver month on month
increases in revenue and test numbers.

Chair of Pacific Edge, Chris Gallaher, said: “The achievement of significant commercial milestones has positioned
Pacific Edge to take advantage of growth opportunities in markets of scale, particularly the US. While test sales
and revenue are already growing, additional capital will enable Pacific Edge to accelerate the execution of our
growth strategy and capitalise on opportunities. The ASX dual listing combined with an equity raise offers a
number of benefits for the Company and shareholders including access to a wider pool of healthcare and other
investors, increased liquidity, the opportunity for further analyst coverage and an acceleration in commercial
activity.”

Details of the Placement

Pacific Edge intends to undertake a Placement of new shares to raise around NZ$60* million (A$58.1 million).
The institutional bookbuild and Placement will occur while Pacific Edge is in trading halt, with participants
expected to include a range of institutional and wholesale investors from New Zealand, Australia and
internationally. A trading halt has been granted by NZX prior to the market opening today.

Bell Potter Securities Limited, Forsyth Barr Limited and Jarden Securities Limited are the Joint Lead Managers for
the Placement.

Details of the Retail Offer

Following completion of the Placement, Pacific Edge intends to offer Eligible Shareholders
2
in New Zealand the
opportunity to participate in a Retail Offer, to raise up to a further NZ$20 million** (A$19.4 million). Each Eligible
Shareholder will be entitled to subscribe for up to NZ$50,000 of new shares under the Retail Offer. Shares will be
offered at the lower of the price paid for shares under the placement and the volume weighted average price of
Pacific Edge's shares on the NZX over the 5-day trading period before the closing date of the retail offer (being 13
October 2021, unless extended). The full terms of the Retail Offer will be contained in the Retail Offer document
which will be distributed to all Eligible Shareholders in due course.

Pacific Edge concludes that the Retail Offer will cater for a high majority of the Company’s non institutional
shareholders, enabling them to participate and potentially increase their relative percentage holdings in Pacific
Edge.

The Pacific Edge shares to be issued under both the Placement and Retail Offer will rank equally in all respects
with Pacific Edge’s existing ordinary shares.

2
Eligible Shareholder means a person who, at 5.00pm on the Record Date, is registered as a PEB shareholder and whose
address (as recorded on the share register) is in New Zealand.
* With the ability for Pacific Edge to increase the size of the placement at its discretion.
** With the ability to accept oversubscriptions, subject to demand and at the discretion of the Board

Company Announcement
23 September 2021

Key dates relating to the Placement and Retail Offer are set out below.

Additional Information

Additional information regarding the equity raising is contained in the presentation which accompanies this
announcement. The presentation contains important information including key risks and foreign selling
restrictions with respect to the capital raising. Nothing contained in this announcement constitutes investment,
legal, tax or other advice. Investors should seek appropriate professional advice before making any investment
decision.

A cleansing notice and corporate action notice also accompany this announcement.

Capital Raise Timetable

Record Date – Retail Offer 5:00pm (NZST) on 22 September 2021
Announcement of capital raise 23 September 2021
Announce completion of placement and trading halt lifted on NZX No later than immediately prior to
market open on 24 September 2021
Opening Date – Retail Offer opens and offer document distributed
to eligible shareholders
28 September 2021
ASX settlement of Placement 29 September 2021
Allotment and trading of Placement shares on ASX commences
Settlement, allotment and trading of Placement shares on NZX
commences
30 September 2021
Closing date - Retail Offer 13 October 2021
Settlement, allotment and trading of Retail Offer shares commences 20 October 2021

All dates and times are indicative only and subject to change.

ENDS

Conference call details

Pacific Edge will host a conference call to discuss the offer at 11.00am NZST on Thursday 23 September 2021.
Participants can join the zoom call at:
https://us02web.zoom.us/j/85644419084?pwd=UlVrTXNwVU1LVzZjS01lTitMdVF2QT09
Meeting ID: 856 4441 9084
Passcode: 421572

This announcement has been prepared for publication in New Zealand and may not be released to US wire
services or distributed in the United States. This announcement does not constitute an offer to sell, or a
solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in
this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be
offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the

Company Announcement
23 September 2021
US Securities Act and applicable US state securities laws. Shares under the Retail Offer will not be offered or sold
to persons resident in the United States.

For more information contact: David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

For media assistance, please contact: Jackie Ellis, P: +64 27 246 2505 E: jackie@ellisandco.co.nz


OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management
of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally
through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and
validated in international multi-centre clinical studies.


Refer to www.cxbladder.com for more information.

---

PACIFIC EDGE
CAPITAL RAISING PRESENTATION
23 SEPTEMBER 2021

IMPORTANT NOTICE AND DISCLAIMER
Information of a general nature
This presentation has been prepared by Pacific Edge Limited (PEL). The information in this presentation is of a general nature
and does not purport to be complete nor does it contain all the information which a prospective investor may require in
evaluating a possible investment in PEL or that would be required in a product disclosure statement, prospectus, or other
disclosure document for the purposes of the New Zealand Financial Markets Conduct Act 2013 (FMCA) or the Australian
Corporations Act 2001 (Cth). PEL is subject to a disclosure obligation that requires it to notify certain material information to
NZX Limited (NZX) and ASX Limited (ASX) for the purpose of that information being made available to participants in the market
and that information can be found by visiting www.nzx.com/companies/PEBand www.asx.com.au. This presentation should be
read in conjunction with PEL’s other periodic and continuous disclosure announcements released to NZX.
Proposed offer
This presentation has been prepared by PEL in relation to the proposed offer of fully paid ordinary shares in PEL (New Shares)
pursuant to a private placement to institutional and other selected investors, and subsequent share purchase plan for existing
shareholders with a registered address in New Zealand, in each case under clause 19 of Schedule 1 of the FMCA (Offer). PEL
reserves the right to vary the dates of the Offer (either generally or in particular cases) or to withdraw the Offer without prior
notice.
Notwithstanding the proposed Offer, this presentation is for information purposes only and is not itself an invitation or offer of
financial products for subscription, purchase or sale in any jurisdiction. Any decision to purchase New Shares in the Offer must
be made on the terms set out in a separate offer document (Offer Document). Any shareholder or investor who wishes to apply
for New Shares under the Offer will need to apply in accordance with the instructions contained in the Offer Document.
NZX
The New Shares have been accepted for quotation by NZX and will be quoted on the NZX Main Board following completion of
allotment procedures. However NZX accepts no responsibility for any statement in this document. NZX is a licensed market
operator, and the NZX Main Board is a licensed market regulated under the FMCA.
ASX
PEL has been admitted to the official list of ASX as a foreign exempt issuer, immediately prior to the announcement of the Offer.
PEL shares will commence trading on ASX following completion of the private placement. PEL will apply for quotation of the
New Shares on the market operated by ASX following completion of the allotment procedures. ASX does not accept any
responsibility for any statements in this document.
Not financial product advice
This presentation does not constitute legal, financial, tax, financial product advice or investment advice or a recommendation to
acquire PEL securities, and has been prepared without taking into account the objectives, financial situation or needs of
investors. Before making an investment decision, prospective investors should consider the appropriateness of the information
having regard to their own objectives, financial situation and needs and consult an NZX Firm, solicitor, accountant or other
professional advisor if necessary.
Forward-looking statements
This presentation contains forward-looking statements that reflect PEL’s current views with respect to future events. Forward-looking
statements, by their very nature, involve inherent risks and uncertainties. Many of those risks and uncertainties are matters which are
beyond PEL’s control and could cause actual results to differ from those predicted. Variations could either be materially positive or
materially negative. The information is stated only as at the date of this presentation. Except as required by law or regulation (including the
NZX Listing Rules and ASX Listing Rules), PEL undertakes no obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. To the maximum extent permitted by law, the directors of PEL, PEL and anyof its
related bodies corporate and affiliates, and their respective officers, partners, employees, agents, associates and advisers do not make any
representation or warranty, express or implied, as to the accuracy, reliability or completeness of such information, or the likelihood of
fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement, and disclaim all
responsibility and liability for these forward-looking statements (including, without limitation, liability for negligence).
Financial data
All dollar values are in New Zealand dollars unless otherwise stated.
This presentation should be read in conjunction with, and subject to, the explanations and views of future outlook on market
conditions, earnings and activities given in the announcements relating to the results, and annual report, for the year ended31March
2021.
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject tothe effect
of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.
Past performance
Investors should note that past performance, including past share price performance, cannot be relied upon as an indicator of(and
provides no guidance as to) future PEL performance, including future financial position or share price performance.
Investment risk
An investment in securities of PEL is subject to investment risk and other known and unknown risks, some of which are beyond the
control of PEL. PEL does not guarantee any particular return or the performance of PEL.
Distribution of presentation
This presentation must not be distributed in any jurisdiction to the extent that its distribution in that jurisdiction is restricted or
prohibited by law or would constitute a breach by PEL of any law. The distribution of this presentation in jurisdictions outsideNew
Zealand may be restricted by law, and persons into whose possession this presentation comes should observe any such restrictions.
Any failure to comply with such restrictions may violate applicable securities laws. None of PEL, any person named in this presentation
or any of their affiliates accept or shall have any liability to any person in relation to the distribution or possession of this presentation
from or in any jurisdiction.
Not for distribution or release in the United States
This presentation is not for distribution or release in the United States. This presentation does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities in the United States. The New Shares have not been, and will not be, registered under the
US Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction of the United States, and may not be
offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US SecuritiesAct of
1933, as amended, and applicable US state securities laws.
Disclaimer
This presentation has been authorised for release to NZX and ASX by PEL’s board of directors. None of PEL’s advisers or any of their
respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorised, permitted or
caused the issue, submission, dispatch or provision of this presentation and, except to the extent referred to in this presentation, none
of them makes or purports to make any statement in this presentation and there is no statement in this presentation which is based
on any statement by any of them.
To the maximum extent permitted by law, PEL and its advisers, affiliates, related bodies corporate, nor their respective directors,
officers, partners, employees and agents:
•exclude and disclaim all liability for any expenses, losses, damages or costs incurred by investors as a result of investors'
participation in the Offer and/or the information in this presentation being inaccurate or incomplete in any way for any reason,
whether by negligence or otherwise; and
•make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information
in this presentation; and none of them shall have any liability (including for negligence).arising in connection with this
presentation or the information contained in it.
By receiving this presentation, you agree to the above terms and conditions. All information in this presentation is providedasat 22
September 2021
2

CONTENTS
1.EXECUTIVE SUMMARY
2.CAPITAL RAISING OVERVIEW
3.COMMERCIAL AND STRATEGIC PROGRESS
APPENDICES
A.THE GLOBAL OPPORTUNITY FOR CXBLADDER
B.KEY RISKS & FOREIGN SELLING RESTRICTIONS
3

EXECUTIVE SUMMARY
A globally focused cancer
diagnostics company specialising
in developing and
commercialising molecular
diagnostic tests that address
large unmet needs in the
detection and management
of cancer

PACIFIC EDGE AT A GLANCE
A GLOBAL CANCER DIAGNOSTICS COMPANY
Validated and class leading suite of Cxbladder products
•Four urine-based diagnostic tests (Cxbladder) for the detection and management of
Urothelial Cancer (UC)
•First new molecular diagnostic tests to be commercially reimbursed in the U.S. for UC in
19 years
•Commercial sales in New Zealand, Australia, Singapore and the U.S.
•CMS reimbursement and product specific CPT codes for Cxbladder Detect and Cxbladder
Monitor
Portfolio of intellectual property and clinical evidence
•Products are underpinned by extensive clinical evidence published in top-tier
international journals
•Potential to leverage existing intellectual property into new product development for the
detection and management of other cancers that can be detected in urine
Compelling growth opportunity
•Annual addressable market (AAM) for Cxbladder in the U.S. estimated to be more than
US$3.5b
*
•Laboratory infrastructure in place in New Zealand and the U.S. with a combined design
capacity for 300k tests per annum
•Dedicated and growing US sales force in place to drive test growth
* Pacific Edge estimate, discussed further on slide 19
5

FY21 WAS A YEAR OF ACHIEVEMENT
SIGNIFICANT COMMERCIAL AND FINANCIAL MILESTONES DRIVE GROWTH
New Zealand
•More than 70% of New Zealand’s population now have access to
Cxbladderthrough contract coverage by their public healthcare
providers
United States
•CMS reimbursement for Cxbladder Detect and Cxbladder Monitor
•Commercial agreement with Kaiser Permanente for Cxbladder
tests
•Increased specialist sales force on ground in U.S.
•Federal Supply Schedule and contract price for Veterans
Administration (achieved prior to FY21)
Global
•Publication of clinical evidence highlighting the clinical utility of
Cxbladder
•Continuing evaluation and use of Cxbladder by large healthcare
institutions
•Strong (76%) growth in operating
revenue across FY21
•Significant (52%) increase in cash
receipts across FY21
•Reduction in monthly cash burn
•Clear (25%) improvement in net loss
after tax across FY21
•Inclusion in the S&P NZX 50 index
Financial MilestonesCommercial Milestones
6

STRENGTHENED TEAM
SENIOR MANAGEMENT & BOARD OF DIRECTORS
Global Executive Team
Chief Executive OfficerDavid Darling*
Chief Financial OfficerGrant Gibson
Chief Operational OfficerDemi Stefanova
Chief Information Systems &
Decision Support
Andy McIntosh
Chief Technical OfficerJustin Harvey
VP Commercial & FranchiseBrent Pownall
VP Clinical Science & Product
Performance
Tony Lough
PEDUSA Executive Team
Executive Chairman PEDUSADavid Levison
CEO PEDUSAJackie Walker
VP Sales & Customer Service
PEDUSA
Jack Atchason
Chief Medical Officer and
Laboratory Director PEDUSA
Thomas Nifong
VP Marketing PEDUSAGerhard Schultz
New appointments in the past 12 months add expertise and experience as Pacific Edge accelerates its global growth
strategy
Appointed in last 12 months
7
Board of Directors
Chairman (Australian based)Chris Gallaher
ExecutiveDirectorDavid Darling
Independent Directors:
•NZ based
•NZ based
•Australian based
Anatole Masfen
Sarah Park
Bryan Williams
Independent Directors
appointed in 2021
(NZ based)
Mark Green
Anna Stove
* David Darling is retiring as CEO in April 2022, but will consult to the company for up to 2 years thereafter

0
2
4
6
8
10
12
Total RevenueOperating RevenueCash Receipts
$Millions
Key financial metrics
FY20FY21
FY21 DELIVERED STRONG IMPROVEMENT ACROSS KEY FINANCIAL METRICS,
DESPITE THE IMPACT OF COVID-19*
✓101% increase in total revenue
✓76% increase in operating revenue
✓25% improvement in net loss after tax
✓52% increase in cash receipts
8
*Covid-19 impacted Pacific Edge’s commercial programme in FY21 and continues
to have an impact in FY22. Despite this, Pacific Edge has continued to grow

The first quarter of FY22
*
was a record quarter for
Cxbladder test volumes and cash receipts
Q1 FY22 Total Laboratory Throughput:
✓Up 79% on Q1 FY21
✓Up 9% on Q4 FY21
✓Up 35% on quarterly average in FY21
Q1 FY22 Cash Receipts:
✓Up 142% on Q1 FY21
✓Up 21% on Q4 FY21
✓Up 50% on quarterly average in FY21
5,356
2,000
3,000
4,000
5,000
6,000
Q1 21Q2 21Q3 21Q4 21Q1 22
Test Numbers
Total Laboratory Throughput
9
* Three months ended 30 June 2021 (unaudited)
GROWTH CONTINUES IN FY22

10
OUTLOOK
▪Pacific Edge has a defined growth strategy and is well positioned to capitalise on recent
commercial milestones
▪The U.S. remains Pacific Edge’s primary near term focus:
▪An increasing number of commercially reimbursed tests from CMS and Kaiser
Permanente covered patients are currently expected to underpin strong revenue
growth and growth in cash receipts in FY22 and beyond;
▪Positive results from the recent scale-up of U.S. commercial operations are now
starting to be seen;
▪United Healthcare* coverage provides validation supporting the potential adoption
and coverage of Cxbladderwith other private payers in the U.S.
▪Strong growth continues in New Zealand with customers moving to multiple Cxbladder
products in mainstream use
▪Southeast Asia has the potential to become a market of scale over time with an accessible
population base larger than the U.S.
▪Australia is in the early stages of commercial take-up and there exists an opportunity to
deliver sales and volume growth
▪Potential to develop and grow new product opportunities by leveraging the company’s
intellectual property across other cancers that can be detected in urine
* Currently Medicare Advantage policyholders

CAPITAL RAISING OVERVIEW

RAISING CAPITAL TO ACCELERATE GROWTH
AND ASX DUAL LISTING
•Pacific Edge’s priority is to ensure it has the resources and capacity to capitalise on its recent commercial milestones and to
execute and accelerate its growth strategy in markets of scale
•Funds raised will be used as follows:
•The majority ofthe funds will be used to accelerate penetration in the company’s key U.S. market
•To further grow in Southeast Asia
•To further leverage the company’s first mover advantage in the detection and management of urothelial cancer
•To potentially develop and grow new product opportunities by leveraging the company’s intellectual property across
other cancers that can be detected in urine
•To maintain a prudent cash buffer for balance sheet management and working capital purposes as the company
transitions to profitability
•Pacific Edge was admitted to the official list of ASX as a foreign-exempt issuer on 22 September 2021 and currently expects
that its shares will be commence trading on the ASX on 27 September 2021
•Pacific Edge intends to maintain its primary listing on the NZX, and is committed to remaining a New Zealand company with
its head office domiciled in New Zealand
12

CAPITAL RAISING OVERVIEW
Offer size and
structure
•An equity raising, comprising:
•A NZ$60 million (A$58.1 million)* Placement, equating to 5.6% of Pacific Edge’s current market capitalisation
•A NZ$20 million (A$19.4 million) Retail Offer (with the ability to accept over subscriptions at the Board's discretion)
Placement
Offer Price
•The Placement Offer Price will be determined via a bookbuild process,with further details on bookbuild participation to
be provided by the Joint Lead Managers
Retail Offer
details
•Pacific Edge is offering up to NZ$20 million (A$19.4 million) of newly issued ordinary shares (with the ability to accept over
subscriptions at the Board's discretion) to Pacific Edge’s eligible existing shareholders resident in New Zealand (up to a
maximum of NZ$50,000 per shareholder) under a Retail Offer:
•The Retail Offer will be priced at the lower of the Placement Price or five day VWAP on NZX during the last five days
of the Retail Offer period
Ranking
•The new shares to be issued under both the Placement and Retail Offer will on allotment rank equally in all respects with
Pacific Edge’s existing ordinary shares
Arrangers
•Bell Potter, Forsyth Barr and Jarden are acting as Joint Lead Managers
•Neither the Placement or the Retail Offer are underwritten
13
*Pacific Edge and the Joint Lead Managers reserve the right to vary the size of the placement based on the size, quality and price level of investor demand
* Based on aNZD/AUD exchange rate of 0.9683 at22 September 2021

INTENDED USE OF PROCEEDS
ACCELERATE MARKET
PENETRATION IN THE
U.S. AND SOUTHEAST
ASIA
Accelerate U.S. market penetration (40-50% of funds raised):
•Key growth initiatives include:
-Initiate commercial launch of CxbladderResolve and the use of multiple Cxbladdertests used in
combination, in FY22
-Accelerate U.S. market penetration with new account managers, commercial support and increased
marketing and advertising spend:
•targeting increased Cxbladder adoption and sales through growing usage by existing customers,
including large urology groups, large national customers, community practices and private payers
-Generation and publication of new clinical evidence to support additional U.S. guideline inclusion and
greater adoption of Cxbladder
Initiate and develop new commercial business of scale in Southeast Asia (10-20% of funds raised):
•Key growth initiatives include:
-Establish dedicated sales teams targeting Singapore, Indonesia, Philippines, Thailand and Malaysia, as
large markets with healthcare models suited to the use of Cxbladder
-Publication of clinical evidence from recently completed User Programs from five public hospitals in
Singapore
-Develop and grow existing and new commercial relationships with large private healthcare providers
-Evaluate the opportunity to increase usage of Cxbladder with public healthcare providers
14
The information above details the intended use of funds by Pacific Edge as at the date of this presentation.
The actual allocations may differ from those indicated above

LEVERAGE FIRST
MOVER ADVANTAGE
IN UROTHELIAL
CANCER AND IP
PORTFOLIO
Further leverage first mover advantage (20-30% of funds raised):
•Pacific Edge is uniquely positioned with strong first mover advantage in the detection of urothelial cancer and
multiple Cxbladder products. It has taken years of investment to develop, validate and protect its IP and has
achieved major U.S. reimbursement milestones, including CMS
•Capital raised will assist to sustain and leverage this competitive advantage to drive sales growth
•Key growth initiatives include:
-Evaluating new product technologies and platforms to maximise performance for the existing Cxbladder
product portfolio, cementing Cxbladder as the standard of care for the detection and management of
urothelial cancer
-Further increase Cxbladder’s portfolio of clinical evidence through additional clinical studies, with clinical
study outputs closely aligned to guideline inclusion
-Potentially developing and growing new product opportunities by leveraging the company’s intellectual
property across other cancers that can be detected in urine
BALANCE SHEET
MANAGEMENT
AND WORKING
CAPITAL
Balance sheet flexibility (20-30% of funds raised):
•Pacific Edge’s cash balance as at 31 August 2021 was $16.2 million, with the monthly cash burn for the last 12
months averaging $1.36 million per month
•Pacific Edge considers it prudent to maintain a cash buffer, for balance sheet management and working capital
purposes as the company transitions to profitability
15
INTENDED USE OF PROCEEDS
(CONT)
The information above details the intended use of funds by Pacific Edge as at the date of this presentation.
The actual allocations may differ from those indicated above

TIMETABLE
Placement
Placement conducted under trading halt23 September 2021
Announce completion of placement and trading halt lifted on NZX
No later than immediately prior to market
open on 24 September 2021
Settlement, allotment and trading of placement shares on NZX commence30 September 2021
ASX dual listing
Pacific Edge admitted to official list of the ASX22 September 2021
Pacific Edge shares commence trading on the ASX 27 September 2021
ASX settlement of placement29 September 2021
ASX allotment of placement shares and tradingof placement shares on the ASX30 September 2021
Retail Offer
Record date5.00pm on 22 September 2021
Retail Offer opens and documentation sent to eligible shareholders28 September 2021
Retail Offer closes13 October 2021
Retail Offer settlement, shares allotted and commencement of trading20 October 2021
16
Dates are subject to change at the discretion of Pacific Edge

COMMERCIAL AND STRATEGIC
PROGRESS
New Zealand
•Continued commercial adoption of Cxbladder,
with the objective to complete coverage of the
New Zealand population
United States
•CMS reimbursement
•Kaiser Permanente
•United Healthcare*
•Scale up of U.S. commercial operations
•Federal Supply Schedule contract
Global
•Clinical evidence
•Continuing evaluation and use of Cxbladder by
large healthcare institutions
* Medicare Advantage

NEW ZEALAND IS LEADING THE GLOBAL ADOPTION OF CXBLADDER
•More than 70% of New Zealand’s population now have
access to Cxbladder through contract coverage by their
public healthcare providers, who have adopted
Cxbladder into commercial mainstream use and their
standard of care
•New electronic guideline ‘Health Pathways’ with
Cxbladder Triage and imaging for all haematuria patients
-replacing previous gold standard cystoscopy and other
tests and procedures
18

19
SIGNIFICANT U.S. TOTAL ADDRESSABLE MARKET
A MORE THAN US$3.5 BILLION OPPORTUNITY FOR CXBLADDER PRODUCTS INBOTH THE
EVALUATION OF HAEMATURIA AND MONITORING FOR DISEASE RECURRENCE
U.S. ANNUAL
ADDRESSABLE MARKET
MORE THAN 5 MILLION
CXBLADDER TEST
OPPORTUNITIES PER YEAR WITH
AN ESTIMATED ANNUAL
REVENUE POTENTIAL OF MORE
THAN
US$ 3.5 BILLION*
* Pacific Edge estimate

•CMS* reimbursement coverage for Cxbladder Detect and
Cxbladder Monitor from 1 July 2020 at US$760 per test
•CMS related tests (Medicare and Medicare Advantage)
accounted for 67% of U.S. commercial test volumes in FY21
•Cxbladder Detect and Cxbladder Monitor accounted for the
majority of U.S. commercial test volumes in FY21
•Inclusion in the CMS’s Local Coverage Determination (LCD) has
resulted in a significant increase in recognised revenue and cash
receipts –with CMS tests paid in approximately 30 days
•Many global healthcare providers regard CMS reimbursement as
a significant validation –which is expected to pave the way for
wider adoption
The successful LCD decision has allowed Pacific Edge to start
recognising revenue (under NZ IFRS 15) for tests that are
performed on CMS patients (Medicare and Medicare
Advantage) in the US at the CMS price of US$760 per test for
Medicare
REIMBURSEMENT COVERAGE
BY THE CMS PROVIDES A
SIGNIFICANT VALIDATION AND
COMMERCIAL MILESTONE
20
* Centers for Medicare and Medicaid Services: US National insurance payer for all US
citizens over 65 years of age

KAISER PERMANENTE: LARGE COMMERCIAL
CUSTOMER FOR CXBLADDER AND PROVIDES
SIGNIFICANT VALIDATION
•Kaiser Permanente (Kaiser) has concluded a national agreement with Pacific Edge
for Cxbladderproducts
•Kaiser started commercially using Cxbladder Monitor from December 2020,
followed by Cxbladder Triage from August 2021
•Kaiser is utilising Cxbladder’s Patient In-Home Sampling System for its patients,
with the process managed by Pacific Edge
•Kaiser reported approximately 15% of consultations were telehealth prior to
Covid-19. The proportion of telehealth consultations are reported by Kaiser to
have increased to around 95% during Covid-19
•Kaiser is the largest non-profit healthcare provider in the U.S. with over 12 million
members (approximately 3.8% of the U.S. population), 39 hospitals and
approximately 23,000 physicians. Kaiser is reported to manage ~2% of U.S.
urology patients
•Around 800,000 people in the U.S. are reportedly monitored for urothelial cancer,
up to 4 times per year for 5 years
21

•United Healthcare is the largest private healthcare provider in the
U.S. with over 43 million members, including more than 6.5 million
Medicare Advantage policyholders
•Cxbladderis being covered as a ‘medically necessary bladder
tumor marker test’
•Coverage became effective from 1 April 2021 at US$760 per test
•United Healthcare partners with 6,500 hospitals and care facilities
nationwide, and more than 1.2 million physicians and other
providers
CXBLADDER COVERED BY
UNITED HEALTHCARE
22
UNITED HEALTHCARE COVERAGE IS A
SIGNIFICANT REIMBURSEMENT
MILESTONE

•Pacific Edge is growing its US based sales teams to
accelerate the adoption of Cxbladderfollowing the
successful achievement of CMS, Kaiser Permanente and
United Healthcare (Medicare Advantage) commercial
milestones
•An additional 9 account managers added to existing and
new sales territories in the past 8 months
•Continued focus by specialist account managers on
converting large national healthcare providers into
commercial customers
•Continue negotiations with specific targeted healthcare
payers to enter into the network for reimbursement
•Expansion of customer services team to drive Patient In-
Home Sampling System program for Kaiser and others
U.S. LABORATORY DESIGN
CAPACITY:
260,000TESTS P.A
EXPANDING US SALES
TEAM:
25 ACCOUNT MANAGERS
AS AT 30 JUNE 2021
SCALE-UP OF U.S. COMMERCIAL OPERATIONS IS DRIVING GROWTH
PACIFIC EDGE HAS STRENGTHENED ITS U.S. BASED EXECUTIVE AND SENIOR MANAGEMENT TEAM
23

24
PIVOTAL PAPER HIGHLIGHTS
SIGNIFICANT OUTPERFORMANCE
OF CXBLADDER PRODUCTS
•A pivotal, peer-reviewed paper co-authored by leading
U.S. urologists and accepted for publication in the Journal
of Urology
*
•Demonstrates the significant clinical and patient benefits
from the use of a combination of Cxbladder products to
correctly identify haematuria patients who have UC and
segregates those patients with High-Impact Tumours (HIT)
requiring priority investigation
* The Journal of Urology is the official journal of the American Urological
Association (AUA) and the most widely read and highly cited journal in the field
of Urology. The paper was accepted for publication on 8 July 2021
•The paper titled ‘Cxbladder for prioritising patients with high impact
tumours’ evaluates the use of Cxbladder Resolve (CxbR), alone and in
combination with other Cxbladder tests, to identify and prioritise patients at
high risk for UC
•CxbR was designed for use by a physician following a patient’s initial
evaluation using both Cxbladder Triage (CxbT) and Cxbladder Detect (CxbD).
Those patients that test positive to CxbT and then also test positive to CxbD,
will receive the CxbR test.
•CxbR was developed on 863 haematuria patients recruited in the U.S., NZ
and Australia; and then tested, both separately and in combination with
other Cxbladder tests, on a further 548 Kaiser Permanente patients, with
outstanding results
•The paper concluded that CxbR has high sensitivity (92.4%) and specificity
(93.8%) and correctly identified all high-impact tumours (HITs)
•With the sequential use of Cxbladder tests for each patient (CxbT followed
by CxbD followed by CxbR):
•87.6% of patients were correctly ruled out from requiring further
workup;and
•100% of high-impact tumours were accurately identified for prioritised
investigation in both study cohorts
•Sequential use of Cxbladder provided 4.8x greater diagnostic efficiency than
the latest American Urological Association (AUA) guidelines

25
•The evaluation and lookback study was performed by the University of
California San Francisco (UCSF) on a cohort of 52 patients who were being
monitored for urothelial cancer as part of their standard of care
•The lookback study concluded that the use by physicians of Cxbladder
Monitor and Pacific Edge’s Patient-In-Home Sampling System reduced the
number of cystoscopies required and was feasible and safe for patients
being monitored for urothelial cancer during the Covid-19 pandemic
•In addition, the study concluded that Cxbladder could be used to further
stratify low risk patients for decreased surveillance during the pandemic
and beyond
•Pacific Edge management summary of Cxbladder’sperformance in this
publication:
•67% of all patients were ruled out from further work-up
•All patients who were ruled out, that have subsequently been
evaluated at the next scheduled surveillance (91%), had no tumors
and no positive cytology (median 4 months)
•82% of patients with CxbM > 3.5 (not ruled out) received cystoscopy
•50% of whom had biopsies with 86% having high impact tumors
25
RECENT PUBLISHED EVIDENCE
SHOWS SIGNIFICANT
OUTPERFORMANCE OF
CXBLADDER PRODUCTS
American Urological Association’s (AUA)
Journal of Urology is publishing in September
2021 a “real world lookback study”
highlighting the clinical utility of Cxbladder
Monitor being used in the Covid setting for
managing patients outside the clinic
The clinical paper was authored by CarrisaChu, Kevin Li, Maxwell
Meng and SimaPortenfrom the Department of Urology at the
University of California San Francisco. The paper has been published
in September 2021 of the Journal of Urology, the official journal of
the American Urological Association (AUA)
CXBLADDER PROVIDES SIGNIFICANT PATIENT
OUTCOMES IN REAL-WORLD COVID-19 SETTING

LARGE NATIONAL HEALTHCARE PROVIDERS AND PAYERS
TARGETED BY PACIFIC EDGE ACROSS THE U.S., SOUTHEAST ASIA AND AUSTRALASIA
U.S.U.S.SOUTHEAST ASIA
✓Kaiser Permanente (completed)
✓CMS reimbursement (completed)
•Carolina Urologic Research Center
•City of Hope
•Cleveland Clinic
•Cornell
•Fox Chase CC
•Johns Hopkins CC
•MD Anderson
•Moffitt CC
•Ohio State University CC
•Penn State Milton S. Hershey Medical Center
•Rush University
•Thomas Jefferson University
•TriStar Medical Center
•UCLA
✓United Healthcare (completed)*
•University of California-San Diego
•University of California-San Francisco
•University of Chicago
•University of Colorado
•University of Michigan
•University of Minnesota
•University of Oklahoma
•University of Pennsylvania
•University of Southern California
•UT Southwestern
•VA Accounts
•Wellstar
* Medicare Advantage
•Singapore General Hospital
•Tan Tock Seng
•Khoo Tech Puat Hospital
•KK Women’s and Children’s Hospital
•National University Hospital
•Raffles Medical Group
•Gleneagles Private Hospital
AUSTRALIA/NEW ZEALAND
•AUS: Multiple large public hospitals across
Australia
✓NZ: Majority of public healthcare
providers under contract
26

APPENDIX A
THE GLOBAL OPPORTUNITY FOR
CXBLADDER

UROTHELIAL CANCER
IS A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE
•~ 550,000 new cases in 2018
1
•~ 200,000 deaths annually
1
•10th most common cancer globally but 6th most
common in men
1
•High recurrence rates (around 70% recurrence
following treatment)
•Requires regular monitoring
•High detection and management costs with invasive
tests and procedures
•Patient compliance low ~40% leading to an increase
in disease progression
5%
are upper
tract (not
including
kidney)
95%
are bladder
cancer
Ureter
Bladder
Kidney
Urothelial Cancer
1. Bray et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 3 cancers
in 185 countries. Ca Cancer J Clin. 2018;68:394-424
28

~7m patients
present with haematuria
annually and 3.4m are
worked up to look for UC
1
~4m cystoscopies were
performed in 2018
1
(many of which are unnecessary
and are replaceable with a non-
invasive, accurate
diagnostic test)
Approximately 83,730
estimated new cases of
urothelial cancer are expected
in the U.S. in 2021
2
4th most common cancer in
men in the U.S.
3
1 in 42 people will be
diagnosed with UC in their
lifetime
4
More than 800,000 people
living with UC will present
annually up to 4 times a year
for up to 5 years for evaluation
for the recurrence of UC
Average lifetime costs of
US$220,000 per patient
(recurrence rate of around 70%
with expensive surveillance)
1
Direct costs associated with
UC predicted to reach
US$4.9b in 2020
1
Based on direct costs alone,
UC has the highest per patient
treatment costs of any cancer
over the patient lifetime
1
UROTHELIAL CANCER
IS A SIGNIFICANTHEALTHCARE CHALLENGE IN THE U.S.
1.Presentation from Dr Sia Daneshmand (Director of Urologic Oncology and Clinical Research, USC) July 2019
2.NIH National Cancer Institute, 2021
3.American Cancer Society, 2019
4.Bladder Cancer Advocacy Network, 2017
29

EXISTING BLADDER CANCER TESTS AND PROCEDURES
HAVE SIGNIFICANT SHORTCOMINGS...
CYSTOSCOPYCYTOLOGYFISH
USE
Detection of bladder cancerIdentifying urothelial carcinomaConducted as a result of a typical cytology
SOURCE MATERIAL
Endoscopic procedure of the bladder
Whole cells that have sloughed off
tumor and are caught in voided urine
Whole cells that have sloughed off tumor
and are caught in voided urine
RESULTS
Performance does not meet the expectations
of physicians; invasive and expensive
Subjective. High rate of atypical or
suspicious findings
Quantitative (# of cells with aneuploidy.)
Moderate rates of non-diagnostic results
SENSITIVITY
Sensitivity 71% and Specificity 65%
2,3
Very low (32%-62%)
1,2
Poor (39%) with high variability
1
1. BMC Urol. 2016.
2. Konety et al, European Urology, May 2019
3. Mowatt 2011 and Jocham 2007
Cancer
Normal
...they are expensive, invasive and have poor relative performance ... providing significant opportunities for new
diagnostic tests that are cheaper, non-invasive and accurate
30

•Four class leading, urine based diagnostic tests for UC addressing multiple unmet needs
across the clinical pathway:
oCxbladder Triage (CxbT): Front line test for use in the primary evaluation of
haematuria to rule out patients who do not have cancer
oCxbladder Detect (CxbD): For use by urologists for patients who have been referred
for a full UCworkup to detect cancers
oCxbladder Resolve
1
(CxbR): Segregates High ImpactTumours(HIT) from Low Impact
Tumours(LIT) enabling a prioritisation of patients with cancer
oCxbladder Monitor (CxbM): Provides front line identification for urothelialcancer
patients being monitored for recurrence of the disease
•Integrated into standards of care and guidelines for a number of healthcare providers in
New Zealand and the NCCN guidelines in the U.S.
CXBLADDER REVOLUTIONIZES HOW UROLOGISTS
DETECT AND MANAGE UROTHELIAL CANCER
Cxbladder provides better care for patients, better utility for urologists and savings for
healthcare payers
1. U.S. commercial launch of Cxbladder Resolve will be initiated in FY22
31

CXBLADDER IS USED AT MULTIPLE DECISION POINTS ACROSS THE
CLINICAL PATHWAY
Cxbladder
Triage
Cxbladder
Detect
Cxbladder
Resolve
Cxbladder
Monitor
Patient PresentationPrimary DetectionPrimary DetectionUC Surveillance
Risk stratification of patient
✓✓✓
Chronic microhaematuria
✓✓✓
Young, non-smoker, no occupational exposure,
female
✓✓✓
Gross haematuria
✓✓✓
Atypical Cytology
✓✓
Equivocal cystoscopy
✓✓
Prioritisation of High Impact Tumours
✓✓✓
Renal Insufficiency
✓
Upper tract urothelial carcinoma
✓
Surveillance for UC recurrence
✓
32
✓: Optimised for these types of patients
CxbT, CxbD and CxbR used in combination for this setting

CXBLADDER HAS CLASS LEADING PERFORMANCE METRICS:
SENSITIVITY, SPECIFICITY AND NEGATIVE PREDICTIVE VALUE (NPV)
33
Primary Detection of UC -Haematuria
Cxbladder TriageCxbladder DetectCxbladder ResolveCxbladder Monitor
Sensitivity 95%
NPV 99%
Sensitivity 82%
Specificity 85%
NPV 97%
Sensitivity 92%
Specificity 94%
NPV 99%
Sensitivity 93%
NPV 97%
Surveillance of UC
Cxbladder’s high sensitivity and high NPV provide the required confidence to rule out disease and significantly
reduce the need for expensive, invasive tests

CXBLADDER HAS A MULTI-MARKET AND MULTI-PRODUCT GROWTH
OPPORTUNITY
U.S.
75%
Rest of World
25%
Total Laboratory
Throughput
by Region
(as at 31 Mar 2021)
Triage
24%
Detect
53%
Monitor
23%
Total Laboratory
Throughput
by Test Type
(as at 31 Mar 2021)
34

APPENDIX B
KEY RISKS & FOREIGN SELLING
RESTRICTIONS

KEY RISKS
Like any investment, there are risks associated with an investment in Pacific Edge shares. Before investing in Pacific Edge, youshould be aware than an investment in
Pacific Edge has a number of risks, some of which are specific to Pacific Edge and some of which relate to listed securities generally, and many of which are beyond the
control of Pacific Edge. Additionally, some risks may be unknown and other risks, currently believed to be immaterial, couldturn out to be material. Whilst the section
below aims to highlight some of the key risks, it is not exhaustive.
Investors should be aware that the spread of Covid-19 and the actions taken in response by governments in New Zealand and other countries, including border
controls, stay at home measures and travel restrictions, and the resulting effects on the global economy have had, and may continue to have, a material adverse effect
on Pacific Edge, its financial performance and position, liquidity, financial condition and results of operations. It is alsolikely that there will be further unforeseen
negative impacts from the Covid-19 pandemic, of an as-yet unknown magnitude and duration. It is not currently clear when these negative impacts will begin to abate.
Pacific Edge will continue to respond to the challenges facing it, but there is no certainty as to the severity or likelihoodofsuch unforeseen impacts arising nor whether
any mitigating action can be taken or will be effective.
Before deciding whether to invest in Pacific Edge shares, you must make your own assessment of the risks associated with the investment, including the inherent
uncertainties due to the impact of Covid-19 noted above, and consider whether such an investment is suitable for you having regard to all other Pacific Edge
continuous disclosure announcements and publicly available information, and consult your financial adviser and other professional advisers.
36

KEY RISKS
(CONT)
Impact of Covid-
19 on Pacific
Edge
Pacific Edge’s operational and financial performance has been significantly impacted by Covid-19. This includes disruption to supply chains, which
has the potential to impact Pacific Edge’s ability to procure equipment required to provide diagnostic tests; and border closures and travel
restrictions, which limit Pacific Edge’s ability to both undertake in-person sales and marketing activity and recruit highly qualified employees.
General
economic
conditions
Pacific Edge’s operating and financial performance is influenced by a variety of general economic and business conditions in NewZealand, the
United States, Southeast Asia and globally. A prolonged deterioration in general economic conditions, which may lead to a decrease or
reprioritisation of healthcare spending, has the potential to have a material adverse effect on Pacific Edge’s business or financial condition (or
both). This risk is heightened in the current uncertain economic environment.
Competition
The global cancer diagnostics industry is highly competitive, with research undertaken by a large number of commercial and not for profit
institutions globally on new diagnostic tools. There are also a large number of well capitalised diagnostics competitors operating in the industry.
There is a risk that Pacific Edge’s competitors may discover, develop or commercialise products more successfully than Pacific Edge, which could
render Pacific Edge’s products obsolete or otherwise uncompetitive, resulting in adverse effects on Pacific Edge’s revenue, margins and
profitability.
Product and
technology risk
Pacific Edge relies on the performance and reliability of its Cxbladder suite of products, laboratory operations and IT and technical systems. While
the performance of Cxbladder has been demonstrated in various scientific journal publications, any failure of Pacific Edge’s Cxbladder products
and technology systems has the potential to impact Pacific Edge’s business and reputation. Financial and litigation consequencesrelating to
underperformance and unreliability have the potential to be significant.
New product
development
Pacific Edge continues to leverage its suite of patents and intellectual property to explore new products and applications. There is a risk that those
development efforts may not be successful, or may take longer and be more expensive than anticipated, and as a result PacificEdge’s investment
will be delayed or lost. This risk could arise due to a number of factors, including delays in commencement or completion of scientific studies. Any
failure or significant delay in the development of one or more of Pacific Edge’s new products and product extensions may havea material negative
impact on Pacific Edge’s financial performance and growth.
37

KEY RISKS
(CONT)
Litigation
In the ordinary course of conducting its business, Pacific Edge is exposed to potential litigation and other proceedings, including through claims of
intellectual property infringement or breach of agreements. If such proceedings are brought against Pacific Edge, Pacific Edge could incur considerable
defence costs (even if successful), with the potential for damages and costs awards against Pacific Edge if it were unsuccessful, which could have a
significant adverse financial impact on Pacific Edge.
Circumstances may also arise in which Pacific Edge considers that it is reasonable or necessary to initiate litigation or other proceedings, including for
example to protect its intellectual property rights.
Regulatory,
industry body
and guideline
risks
Pacific Edge’s Cxbladderproducts and laboratories are regulated and certified by various government and industry entities in territories and markets
in which the tests are performed and/or sold.Reimbursement for these tests may be influenced by reimbursement rulings from private and/or
government payers.Guidelines issued by various industry bodies also influence the treatment and management regimes for patients, with the
potential to impact on the uptake and use of Cxbladder. If Pacific Edge is unable to retain or, in certain markets, gain inclusion in guidelines, or the
current regulatory approvals and reimbursement obtained for existing products are removed or reduced, such matters could haveanadverse impact
on Pacific Edge’s financial performance and its ability to achieve its business plans.If Pacific Edge is unable to obtain the approvals required for new
products in new territories, or is unable to obtain future reimbursement for new products, this could also have an adverse impact on Pacific Edge’s
financial performance and its ability to achieve its business plans.
Market volatility
of Pacific Edge’s
shares
Any investment in equity capital markets carries general risks. Pacific Edge’s shares are currently listed on NZX, and will be listed on the ASX, and are
subject to the usual market-related forces which impact on Pacific Edge’s share price. There can be no assurance that trading inthe shares following
the offer will not result in the share price trading at levels below the price paid by investors in the offer. The equity markets have in recent times been
subject to pronounced volatility due to the continuing impacts of Covid-19. There is no certainty that this recent volatility will not continue or worsen,
which could have a materially adverse impact on the market price of Pacific Edge shares.
Factors such as the risk factors disclosed in this presentation as well as other factors could cause the market price of PacificEdge’s shares to decline
or to materially fluctuate. It also is possible that new market risks may develop as a result of the New Zealand market experiencing extreme stress, or
due to existing risks (including the impacts of Covid-19) manifesting themselves in ways that are not currently foreseeable.
A weakening in the New Zealand dollar as against other currencies will cause the value of the shares to decline in any portfoliowhich is denominated
in a currency other than New Zealand dollars.
38

FOREIGN SELLING RESTRICTIONS
International Offer Restrictions
This document does not constitute an offer of new ordinary shares (New Shares) of Pacific Edge in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any
person, and the New Shares, may not be offered or sold in any country outside NZ except to the extent permitted below.
Australia
This document and the offer of New Shares are only made available in Australia to persons to whom an offer of securities can be made without disclosure in accordance with applicable exemptions in sections
708(8) (sophisticated investors), 708(11) (professional investors), 761G (wholesale clients) of the Australian Corporations Act 2001 (Cth) (the "Corporations Act"). This document is not a prospectus, product
disclosure statement or any other formal "disclosure document" for the purposes of Australian law and is not required to, anddoes not, contain all the information which would be required in a "disclosure
document" under Australian law. This document has not been and will not be lodged or registered with the Australian Securities &Investments Commission. Prospective investors should not construe anything
in this document as legal, business or tax advice nor as financial product advice for the purposes of Chapter 7 of the Corporations Act.
Hong Kong
WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been
authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). Accordingly, this document may not be
distributed, and the New Shares may not be offered or sold, in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance).
No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in thepossession of any person for the purpose of issue, in Hong Kong or elsewhere that is
directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares
that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that
amount to an offer to the public in Hong Kong within six months following the date of issue of such securities.
The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this
document, you should obtain independent professional advice.
Not for distribution in the United States
This presentation is not for distribution or release in the United States. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The New
Shares have not been, and will not be, registered under the US Securities Act of 1933, as amended, or the securities laws of anystate or other jurisdiction of the United States, and may not be offered or sold in
the United States except in transactions exempt from, or not subject to, registration under the US Securities Act of 1933, asamended, and applicable US state securities laws.
39

---

Corporate Action Notice


Page 1 of 2
Section 1: issuer information (mandatory)
Name of issuer Pacific Edge Limited
Class of Financial Product Ordinary shares
NZX ticker code PEB
ISIN (If unknown, check on NZX
website)
NZPEBE0002S1
Name of Registry Link Market Services Limited
Type of corporate action
(Please mark with an X in the
relevant box/es)
Share purchase plan X Renounceable
Rights issue

Capital
reconstruction
Non
Renounceable
Rights issue

Call Bonus issue
Record Date 22/09/2021
Ex-Date (one business day before
the Record Date)
21/09/2021
Currency NZD
Section 6: Share purchase plans (delete if not applicable)
Number of financial products to be
issued
OR
Maximum dollar amount of
Financial Products to be issued
Up to NZ$50,000 per shareholder/beneficial owner with a
registered address in New Zealand, for an aggregate offer
size of up to NZ$20 million (with Pacific Edge having the
ability to accept oversubscriptions. The first $15,000 of
new shares will be offered under Listing Rule 4.3.1(a)
(share purchase plan) and the additional $35,000 of new
shares offered under Listing Rule 4.5.1 (15% Rule).
Minimum application amount (if
any)
$250.00
Exercise Price The lesser of: (a) the price paid by investors in PEB's
placement announced on 23 September 2021; and (b) the
volume weighted average price of ordinary shares in PEB
on the NZX Main Board over the 5-day trading period prior
to and including the Closing Date (being 7 October 2021
to 13 October 2021, unless the Closing Date is extended).
Scaling reference date By reference to holdings of eligible shareholders at the
Record Date
Closing Date 13/10/2021
Allotment Date 20/10/2021

2 of 2
Section 7: Authority for this announcement (mandatory)
Name of person authorised to
make this announcement
Grant Gibson (CFO, PEB)
Contact person for this
announcement
Grant Gibson (CFO, PEB)
Contact phone number +64 3 479 8500
Contact email address grant.gibson@pelnz.com
Date of release through MAP 23/09/2021

---

2201994 | 6349167v1
23 September 2021
NZX Limited
Level 1, NZX Centre
11 Cable Street
Wellington

ASX Limited
20 Bridge Street
Sydney NSW 2000
PACIFIC EDGE LIMITED (NZX and ASX: PEB): CAPITAL RAISING
NOTICE PURSUANT TO CLAUSE 20(1)(a) OF SCHEDULE 8 TO THE FINANCIAL MARKETS
CONDUCT REGULATIONS 2014 AND CLAUSE 708A(12J) OF THE CORPORATIONS ACT AS
NOTIONALLY INSERTED BY ASIC INSTRUMENT 21-0811
1. Pacific Edge Limited (PEB) has announced that it intends to make an offer consisting of:
a. a placement of NZ$60 million / A$58.1 million (with the ability for PEB to increase the
size of the placement at its discretion); and
b. a retail offer to eligible shareholders in New Zealand, to raise approximately NZ$20
million / A$19.4 million (with the ability for PEB to accept oversubscriptions),
(together the Offer).
2. The Offer is being made in reliance upon the exclusion in clause 19 of Schedule 1 of the
Financial Markets Conduct Act 2013 (FMCA). The Offer is for new fully paid ordinary shares of
the same class as already quoted on the NZX Main Board operated by NZX Limited.
3. This notice is given under clause 20(1)(a) of Schedule 8 of the Financial Markets Conduct
Regulations 2014 (FMC Regulations) and under paragraph 708A(12J) of the Corporations Act
2001 (Cth) (Corporations Act), as notionally inserted by ASIC Instrument 21-0811.
4. PEB will issue the relevant shares under the Offer without disclosure to investors under Part
6D.2 of the Corporations Act.
5. As at the date of this notice:
a. PEB is in compliance with the continuous disclosure obligations that apply to it in
relation to PEB's ordinary shares.
b. PEB is in compliance with its financial reporting obligations.
c. There is no information that is "excluded information" as defined in clause 20(5) of
Schedule 8 of the FMC Regulations in respect of PEB.
d. PEB has complied with its obligations under Rule 1.15.2 of the listing rules of ASX
Limited.
6. The Offer is not expected to have any material effect or consequence on the control of PEB.
On behalf of
Pacific Edge Limited

Chris Gallaher
Chair